DBV Technologies Submitted Peanut Patch Application

The company has formally requested FDA approval for its immunotherapy patch designed to treat peanut allergies in children.

Updated on Sept. 29, 2026 in Allergies

Isometric editorial illustration of a sterile medical patch on a plain laboratory surface. — DBV Technologies has formally submitted a Biologics License Application to the U.S. Food and Drug Administration for its peanut allergy immunotherapy patch. AI Illustration. Upload story photo >

Live Poll

Should the FDA fast-track new immunotherapy treatments for children with food allergies?

DBV Technologies has submitted a Biologics License Application to the FDA for the VIASKIN Peanut Patch. The company is seeking approval to treat peanut allergies in children aged 4 through 7.

Why it matters

The patch uses epicutaneous immunotherapy to desensitize children to peanut allergens by delivering small amounts of protein through the skin. This submission follows the FDA granting the treatment Breakthrough Therapy Designation.

The Phase 3 VITESSE trial enrolled 654 children across 86 sites to test the 250 µg patch. Participants underwent a 12-month double-blind treatment period to evaluate the therapy.

The players

DBV Technologies

A biotechnology company headquartered in Châtillon, France, with North American operations based in Warren, NJ.

FDA

The federal agency responsible for evaluating the safety and efficacy of medical products and biologics for the United States.

The details

The VIASKIN Peanut Patch aims to provide a non-invasive way for children to build tolerance by interacting with immune cells in the skin. The application is supported by the results observed during the year-long VITESSE study.

September 29, 2026: DBV Technologies submitted the Biologics License Application to the FDA.

Allergies
Sept. 23
Crossject and BARDA Expanded ZEPIZURE Development Plan
Allergies
Sept. 22
Experts Released Alopecia Areata Treatment Guidelines
Biotech
Sept. 23
FDA Granted Breakthrough Status to Glycomine Drug

The Big Picture

This submission follows the FDA Breakthrough Therapy Designation program, which is designed to expedite the development and review of drugs for serious conditions. The transition to a formal license application represents the next major milestone in moving this immunotherapy from clinical investigation to potential market availability.

If approved, this patch would offer a new, non-invasive method for families to manage peanut allergies in young children. Caregivers and patients should continue following current avoidance strategies until the FDA reaches a final decision on the application.

The takeaway

The submission of this application is a critical step in the development of non-oral immunotherapy for food allergies. Patients and families waiting for new treatment options should monitor the FDA review process for potential availability timelines.